THE APEX TIMES
An investor letter shared by First Pacific Advisors highlighted Pfizer’s recent share-price strength even as COVID-19 related revenue declines, raising the question of whether the company’s newer product mix can carry a longer-term turnaround.
Pfizer’s shares have risen sharply over the past year even as revenue tied to COVID-19 has continued to contract, according to commentary highlighted in an investor letter released by First Pacific Advisors. In a report syndicated by Yahoo Finance, the firm pointed to Pfizer’s roughly 20% rise while noting that the company’s COVID-related revenue trajectory has been moving in the opposite direction.
The commentary came through First Pacific Advisors’ “FPA Queens Road Value Fund,” which published its Q3 2026 investor letter. The letter described broader portfolio results and included a discussion of Pfizer’s stock performance against the backdrop of declining pandemic-era revenues, framing a central debate for the pharmaceutical market: whether new product offerings can replace fading blockbuster demand as companies move past emergency use and mass vaccination cycles.
While the Yahoo Finance report summarized the letter’s central question, it did not provide enough detail to confirm which specific Pfizer products were emphasized, what time horizon the manager used, or how the firm assessed the durability of growth from the company’s post-COVID pipeline. The framing in the headline, however, suggests the manager is looking for evidence that Pfizer’s newer portfolio can drive results that are less dependent on COVID-19.
Beyond Pfizer, the investor communication also reported the fund’s third-quarter performance. The Yahoo Finance article said the “FPA Queens Road Value Fund” returned -1.82% in the third quarter, placing the Pfizer discussion inside a broader context of fund-level outcomes rather than presenting it as an isolated bet.
For investors, that combination is notable. Pfizer’s challenge is common across the sector’s large incumbents that benefited from pandemic demand and then faced a rapid normalization in volumes. Even when shares rebound, analysts and long-term holders tend to focus on whether pipeline execution, product lifecycle management, and commercial expansion can offset the loss of COVID-era income streams.
At the same time, the summary available in the Yahoo Finance post does not clarify how the manager quantified the COVID decline, whether it referred to specific revenue line items, or whether it compared Pfizer’s projected sales trajectory to internal targets or external consensus forecasts. It also does not state whether the “turnaround” framing was tied to near-term catalysts such as regulatory decisions, launch timing, or changes in market access and pricing.
For readers trying to understand what is driving Pfizer’s relative performance, the most consequential unresolved point in the available coverage is evidence. The article’s question implies a belief that the new product portfolio could matter, but the reporting provided here does not include the product-by-product rationale or the valuation assumptions that would connect that belief to the stock’s move.
What to watch next is whether Pfizer’s post-COVID trajectory becomes clearer in its own disclosures. Investors will typically look for updates on sales trends for non-COVID products, pipeline progress, and any guidance changes that speak to durability. The letter’s core theme suggests market attention may remain on the pace at which Pfizer can transition to a more diversified earnings base, even as COVID-related revenue declines continue to play out.
A reported Phase 3 win for Moderna’s personalized melanoma therapy, used alongside Merck’s Keytruda, is prompting fresh optimism that the mRNA platform can expand beyond infectious disease. Still, key details such as magnitude of benefit and full trial disclosure remain to be validated.
The company is pursuing Australian National Immunisation Program listings for its mRNA influenza vaccines after securing a March 2027 agenda spot with the PBAC, a key committee that advises public reimbursement.
The initiative, launched within Aetna, is designed to link a large share of expectant members and their newborns to coordinated maternal and infant care. CVS Health has not, in the reporting, disclosed staffing, clinical protocols, or outcome targets tied to the program.
A recent analyst upgrade focus shifted toward profitability drivers inside Medicare Advantage and the operational momentum of Optum Health, as well as what the bank characterizes as disciplined pricing.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...